AbbVie Bears Load Up on December 2027 Puts as Stock Slides Near 52-Week High

By TrendSpider Editor

AbbVie Inc. (ABBV) is drawing attention in the options market today after two notable put contracts totaling $2,866,500 in combined premium hit the tape, both targeting a $260 strike expiring December 17, 2027. The activity arrives as shares trade at $287.02, down 1.99% on the session, and comes aga

AbbVie Bears Load Up on December 2027 Puts as Stock Slides Near 52-Week High

AbbVie Inc. (ABBV) is drawing attention in the options market today after two notable put contracts totaling $2,866,500 in combined premium hit the tape, both targeting a $260 strike expiring December 17, 2027. The activity arrives as shares trade at $287.02, down 1.99% on the session, and comes against a broad 52-week range of $191.00 to $302.93, placing the stock closer to its annual highs than its lows. The size and open interest ratios on these contracts suggest this is far from routine hedging.

Key Drivers of the ABBV Stock Move

The forward setup for ABBV is a tug of war between a stock trading near multi-year highs and what appears to be a well-funded bearish bet on a longer-term pullback. The 13-month expiration on these puts is notable. Rather than a short-term tactical trade, this positioning suggests the trader is expressing a view that extends well into 2027, potentially tied to pipeline concerns, patent cliff dynamics, or broader sector headwinds in large-cap biopharma. The stock's proximity to its 52-week high of $302.93 means there is limited technical cushion above current levels, while the gap back to the $260 strike gives the puts room to move into the money if sentiment shifts.

ABBV Unusual Options Activity

Two unusual put contracts were flagged in Wednesday's session, both concentrated at the same strike and expiration:

No call-side unusual activity was flagged in today's session. The total unusual premium across both contracts came to $2,866,500, entirely on the put side, with zero unusual call contracts reported.

ABBV Seasonality

Mid-to-late November historically marks a transitional period for large-cap healthcare names as institutional investors rebalance portfolios ahead of year-end. Options positioning with December 2027 expirations placed in November 2026 may also reflect a strategy designed to straddle the company's next several earnings cycles and any anticipated pipeline or regulatory catalysts through the coming year.

ABBV Relative Performance

ABBV is down 1.99% on Wednesday, underperforming on a session basis. With the stock sitting at $287.02 against a 52-week range of $191.00 to $302.93, it remains within roughly 5% of its annual high, indicating that despite today's pullback, the longer-term trend has strongly favored bulls. However, the fresh put activity suggests at least one market participant believes the stock's proximity to its 52-week peak may limit near-term upside while increasing the risk of a larger reversal over the next year.

More on ABBV

Latest Market News